leukemia

Summary

Summary: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. It is classified according to degree of cell differentiation as acute or chronic, and according to predominant type of cell involved as myelogenous or lymphocytic. (Dorland, 28th ed)

Top Publications

  1. ncbi Stem cells, cancer, and cancer stem cells
    T Reya
    Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Palo Alto, California 94305, USA
    Nature 414:105-11. 2001
  2. pmc MiR-15a and miR-16-1 cluster functions in human leukemia
    George A Calin
    Human Cancer Genetics Program and Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 105:5166-71. 2008
  3. doi The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells
    William J Harris
    Cancer Research UK Leukaemia Biology Laboratory, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom
    Cancer Cell 21:473-87. 2012
  4. ncbi Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
    Omer H Yilmaz
    Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine, and Center for Stem Cell Biology, University of Michigan, Ann Arbor, Michigan 48109 2216, USA
    Nature 441:475-82. 2006
  5. ncbi MLL translocations, histone modifications and leukaemia stem-cell development
    Andrei V Krivtsov
    Division of Haematology Oncology, Children s Hospital, Department of Pediatric Oncology, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 7:823-33. 2007
  6. pmc MicroRNA miR-125b causes leukemia
    Marina Bousquet
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Proc Natl Acad Sci U S A 107:21558-63. 2010
  7. pmc Gadd45 stress sensors in malignancy and leukemia
    Dan A Liebermann
    Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, Pennsylvania 19140, USA
    Crit Rev Oncog 16:129-40. 2011
  8. ncbi Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9
    Andrei V Krivtsov
    Division of Hematology Oncology, Children s Hospital, Boston, Massachusetts 02115, USA
    Nature 442:818-22. 2006
  9. pmc Reprogramming of miRNA networks in cancer and leukemia
    Stefano Volinia
    Data Mining for Analysis of Microarrays, Department of Morphology and Embryology, Universita degli Studi, Ferrara 44100, Italy
    Genome Res 20:589-99. 2010
  10. pmc Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction
    Ismael Samudio
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Invest 120:142-56. 2010

Detail Information

Publications341 found, 100 shown here

  1. ncbi Stem cells, cancer, and cancer stem cells
    T Reya
    Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Palo Alto, California 94305, USA
    Nature 414:105-11. 2001
    ....
  2. pmc MiR-15a and miR-16-1 cluster functions in human leukemia
    George A Calin
    Human Cancer Genetics Program and Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 105:5166-71. 2008
    ..In chronic lymphocytic leukemia (CLL), the most common adult human leukemia, miR-15a and miR-16-1 are lost or down-regulated in the majority of ..
  3. doi The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells
    William J Harris
    Cancer Research UK Leukaemia Biology Laboratory, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom
    Cancer Cell 21:473-87. 2012
    Using a mouse model of human MLL-AF9 leukemia, we identified the lysine-specific demethylase KDM1A (LSD1 or AOF2) as an essential regulator of leukemia stem cell (LSC) potential...
  4. ncbi Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
    Omer H Yilmaz
    Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine, and Center for Stem Cell Biology, University of Michigan, Ann Arbor, Michigan 48109 2216, USA
    Nature 441:475-82. 2006
    ..Mechanistic differences between normal stem cells and cancer stem cells can thus be targeted to deplete cancer stem cells without damaging normal stem cells...
  5. ncbi MLL translocations, histone modifications and leukaemia stem-cell development
    Andrei V Krivtsov
    Division of Haematology Oncology, Children s Hospital, Department of Pediatric Oncology, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 7:823-33. 2007
    ..The link between a chromatin modulator and leukaemia stem cells provides support for epigenetic landscapes as an important part of leukaemia and normal stem-cell development...
  6. pmc MicroRNA miR-125b causes leukemia
    Marina Bousquet
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Proc Natl Acad Sci U S A 107:21558-63. 2010
    MicroRNA miR-125b has been implicated in several kinds of leukemia. The chromosomal translocation t(2;11)(p21;q23) found in patients with myelodysplasia and acute myeloid leukemia leads to an overexpression of miR-125b of up to 90-fold ..
  7. pmc Gadd45 stress sensors in malignancy and leukemia
    Dan A Liebermann
    Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, Pennsylvania 19140, USA
    Crit Rev Oncog 16:129-40. 2011
    ..been obtained indicating that Gadd45 proteins can function to either promote or suppress tumor development and leukemia; this is dependent on the molecular nature of the activated oncogene and the cell type, via engagement of ..
  8. ncbi Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9
    Andrei V Krivtsov
    Division of Hematology Oncology, Children s Hospital, Boston, Massachusetts 02115, USA
    Nature 442:818-22. 2006
    ..Our findings define progression from normal progenitor to cancer stem cell, and suggest that targeting a self-renewal programme expressed in an abnormal context may be possible...
  9. pmc Reprogramming of miRNA networks in cancer and leukemia
    Stefano Volinia
    Data Mining for Analysis of Microarrays, Department of Morphology and Embryology, Universita degli Studi, Ferrara 44100, Italy
    Genome Res 20:589-99. 2010
    ..Finally, we experimentally validated the miRNA network with acute lymphocytic leukemia originated in Mir155 transgenic mice...
  10. pmc Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction
    Ismael Samudio
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Invest 120:142-56. 2010
    ..Mitochondrial uncoupling--the continuing reduction of oxygen without ATP synthesis--has recently been shown in leukemia cells to circumvent the ability of oxygen to inhibit glycolysis, and may promote the metabolic preference for ..
  11. pmc Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients
    Masami Tanaka
    Department of Pathology, Tokyo Medical University, Tokyo, Japan
    PLoS ONE 4:e5532. 2009
    ..Recent studies, however, have revealed that microRNAs exist and escape digestion in plasma...
  12. pmc Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
    Matthew R Janes
    Department of Molecular Biology and Biochemistry, Institute for Immunology, University of California Irvine, Irvine, California, USA
    Nat Med 16:205-13. 2010
    ..of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation...
  13. doi The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    James W Vardiman
    Department of Pathology, University of Chicago, IL, USA
    Blood 114:937-51. 2009
    ..In this paper, the classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologists not only ..
  14. ncbi International Classification of Childhood Cancer, third edition
    Eva Steliarova-Foucher
    International Agency for Research on Cancer, Lyon, France
    Cancer 103:1457-67. 2005
    ..This necessitated a third revision of the 1996 International Classification of Childhood Cancer (ICCC-3)...
  15. doi Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses
    Julia Hilpert
    Department of Hematology and Oncology, Eberhard Karls University, D 72076 Tuebingen, Germany
    J Immunol 189:1360-71. 2012
    ..Likewise, relevant expression of NKG2DL in leukemia has been reported by some, but not all studies...
  16. ncbi Human microRNA clusters: genomic organization and expression profile in leukemia cell lines
    Jia Yu
    National Laboratory of Medical Molecule Biology, Institute of Basic Medical Sciences, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100005, China
    Biochem Biophys Res Commun 349:59-68. 2006
    ..Then we performed Northern blot analysis for expression profiling of all clustered miRNAs in several human leukemia cell lines...
  17. ncbi The roles of FLT3 in hematopoiesis and leukemia
    D Gary Gilliland
    Brigham and Women s Hospital, Howard Hughes Medical Institute, Boston, MA, USA
    Blood 100:1532-42. 2002
    ..Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small number of patients with acute lymphocytic leukemia or myelodysplastic syndrome...
  18. pmc Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
    Alberto M Martelli
    Department of Human Anatomy, University of Bologna, Cellular Signalling Laboratory, Bologna, Italy
    Oncotarget 3:371-94. 2012
    ..In preclinical models, dual PI3K/mTOR inhibitors displayed a much stronger cytotoxicity against acute leukemia cells than either PI3K inhibitors or allosteric mTOR inhibitors, such as rapamycin...
  19. pmc Cell intrinsic alterations underlie hematopoietic stem cell aging
    Derrick J Rossi
    Department of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 102:9194-9. 2005
    Loss of immune function and an increased incidence of myeloid leukemia are two of the most clinically significant consequences of aging of the hematopoietic system...
  20. ncbi hDOT1L links histone methylation to leukemogenesis
    Yuki Okada
    Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Cell 121:167-78. 2005
    ..Here we report that hDOT1L interacts with AF10, an MLL (mixed lineage leukemia) fusion partner involved in acute myeloid leukemia, through the OM-LZ region of AF10 required for MLL-AF10-..
  21. pmc FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors
    Jennifer O'Neil
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Exp Med 204:1813-24. 2007
    ..To clarify the basis for GSI resistance in T cell acute lymphoblastic leukemia (T-ALL), we studied T-ALL cell lines with constitutive expression of the NOTCH intracellular domain (NICD), but ..
  22. doi A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway
    Xinliang Mao
    Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou, China
    Blood 117:1986-97. 2011
    D-cyclins are universally dysregulated in multiple myeloma and frequently overexpressed in leukemia. To better understand the role and impact of dysregulated D-cyclins in hematologic malignancies, we conducted a high-throughput screen for ..
  23. doi CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers
    J A Burger
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Leukemia 23:43-52. 2009
    ..Activation of CXCR4 induces leukemia cell trafficking and homing to the marrow microenvironment, where CXCL12 retains leukemia cells in close contact ..
  24. pmc Leukemia gene atlas--a public platform for integrative exploration of genome-wide molecular data
    Katja Hebestreit
    Institute of Medical Informatics, University of Muenster, Muenster Germany
    PLoS ONE 7:e39148. 2012
    ..We developed the Leukemia Gene Atlas (LGA) as a public platform designed to support research and analysis of diverse genomic data published ..
  25. pmc Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest
    Juan C Acosta
    Cancer Molecular Biology Group, Department of Molecular Biology, Instituto de Biomedicina y Biotecnología de Cantabria, Universidad de Cantabria CSIC IDICAN, Santander, Spain
    Mol Cell Biol 28:7286-95. 2008
    ..We have established a genetically defined differentiation model in human leukemia K562 cells by conditional expression of the cyclin-dependent kinase (Cdk) inhibitor p27 (inducible by Zn(2+)) and ..
  26. doi New insights to the MLL recombinome of acute leukemias
    C Meyer
    Diagnostic Center of Acute Leukemia, Institute of Pharmaceutical Biology, ZAFES, University of Frankfurt, Frankfurt Main, Germany
    Leukemia 23:1490-9. 2009
    ..Genomic DNA was isolated from individual acute leukemia patients to identify and characterize chromosomal rearrangements involving the human MLL gene...
  27. doi HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells
    L Liu
    Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, Hunan, People s Republic of China
    Leukemia 25:23-31. 2011
    ..However, the role of autophagy in leukemia still remains largely unknown...
  28. pmc Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates
    Emmanuelle Passegue
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Exp Med 202:1599-611. 2005
    ....
  29. doi Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
    L S Steelman
    Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA
    Leukemia 25:1080-94. 2011
    ..MEK)/extracellular signal-regulated kinase (ERK) pathway is often implicated in sensitivity and resistance to leukemia therapy...
  30. ncbi JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
    L S Steelman
    Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA
    Leukemia 18:189-218. 2004
    ..Small molecular weight cell membrane-permeable drugs that target these pathways have been developed for leukemia therapy...
  31. pmc NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth
    Teresa Palomero
    Institute for Cancer Genetics and Joint Centers for Systems Biology, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 103:18261-6. 2006
    ..plays a critical role during T cell development and in the pathogenesis over 50% of human T cell lymphoblastic leukemia (T-ALL) cases. However, little is known about the transcriptional programs activated by NOTCH1...
  32. pmc Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?
    Emmanuelle Passegue
    Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 100:11842-9. 2003
    b>Leukemia can be viewed as a newly formed, abnormal hematopoietic tissue initiated by a few leukemic stem cells (LSCs) that undergo an aberrant and poorly regulated process of organogenesis analogous to that of normal hematopoietic stem ..
  33. doi Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group
    Torsten Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany
    J Clin Oncol 28:2529-37. 2010
    The Microarray Innovations in Leukemia study assessed the clinical utility of gene expression profiling as a single test to subtype leukemias into conventional categories of myeloid and lymphoid malignancies.
  34. doi European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update
    J Maertens
    Department of Hematology, Leukemia and Stem Cell Transplantation Unit, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium
    Bone Marrow Transplant 46:709-18. 2011
    ..Blood and Marrow Transplantation, the European Organization for Treatment and Research of Cancer, the European Leukemia Net and the Immunocompromised Host Society created the European Conference on Infections in Leukemia (ECIL)...
  35. doi Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway
    Kil Nam Kim
    Jeju Biodiversity Research Institute JBRI, Jeju, Republic of Korea
    Toxicol In Vitro 24:1648-54. 2010
    ..a natural biologically active substance isolated from Ishige okamurae, evidences antitumor activity in human leukemia cell HL-60 cells via the induction of apoptosis...
  36. pmc Zebrafish screen identifies novel compound with selective toxicity against leukemia
    Suzanne Ridges
    Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA
    Blood 119:5621-31. 2012
    ..in vertebrates and induces long-term remission in adult zebrafish with cMYC-induced T-cell acute lymphoblastic leukemia (T-ALL)...
  37. pmc Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
    Scott R Daigle
    Epizyme, Inc, 400 Technology Square, Cambridge, MA 02139, USA
    Blood 122:1017-25. 2013
    ..that the histone methyltransferase DOT1L is required for the development and maintenance of MLL-rearranged leukemia in model systems...
  38. pmc Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia
    Marko Skrtic
    Campbell Family Cancer Research Institute, Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada
    Cancer Cell 20:674-88. 2011
    ..Tigecycline selectively killed leukemia stem and progenitor cells compared to their normal counterparts and also showed antileukemic activity in mouse ..
  39. pmc Chronic myeloid leukemia: mechanisms of blastic transformation
    Danilo Perrotti
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 41230, USA
    J Clin Invest 120:2254-64. 2010
    The BCR-ABL1 oncoprotein transforms pluripotent HSCs and initiates chronic myeloid leukemia (CML)...
  40. pmc High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia
    Wing Leung
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 118:223-30. 2011
    We evaluated 190 children with very high-risk leukemia, who underwent allogeneic hematopoietic cell transplantation in 2 sequential treatment eras, to determine whether those treated with contemporary protocols had a high risk of relapse ..
  41. doi Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
    A M Martelli
    Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell Apparato Locomotore, Universita di Bologna, Bologna, Italy
    Leukemia 25:1064-79. 2011
    ..Although rapamycin and novel rapalogs are usually cytostatic and not cytotoxic for leukemic cells, novel inhibitors that target the kinase activities of PI3K and mTOR may prove more effective for leukemia therapy.
  42. doi Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylation
    Kazuto Suganuma
    Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
    Leuk Lymphoma 51:2112-9. 2010
    ..We examined the energy metabolism of four leukemia cell lines by using glycolysis inhibitor, 2-deoxy-d-glucose (2-DG) and inhibitor of oxidative phosphorylation, ..
  43. doi Epigenetic regulation of miRNA genes in acute leukemia
    X Agirre
    Oncology Area, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain
    Leukemia 26:395-403. 2012
    ....
  44. doi Dietary polyphenols in cancer prevention: the example of the flavonoid quercetin in leukemia
    Carmela Spagnuolo
    Istituto di Scienze dell Alimentazione, Consiglio Nazionale delle Ricerche, Avellino, Italy
    Ann N Y Acad Sci 1259:95-103. 2012
    ..naturally present in the diet and belonging to the class of phytochemicals, is able to sensitize several leukemia cell lines and B cells isolated from patients affected by chronic lymphocytic leukemia (B-CLL), in addition to ..
  45. ncbi Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia
    T Tauchi
    First Department of Internal Medicine, Tokyo Medical University, Shinjuku ku, Tokyo, Japan
    Oncogene 25:5719-25. 2006
    ..In the present study, we investigated the mechanisms of apoptosis induced by telomerase inhibition in acute leukemia. We have found the activation of caspase-3 and poly-(ADP-ribose) polymerase in telomestatin-treated U937 cells (..
  46. pmc Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression
    Akihiko Yokoyama
    Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Mol Cell Biol 24:5639-49. 2004
    MLL (for mixed-lineage leukemia) is a proto-oncogene that is mutated in a variety of human leukemias...
  47. pmc An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase
    Alexander Kohlmann
    Roche Molecular Systems, Inc, Department of Genomics and Oncology, Pleasanton, CA, USA
    Br J Haematol 142:802-7. 2008
    ..standardization programme that was conducted in 11 laboratories as a prephase to the Microarray Innovations in LEukemia (MILE) study...
  48. pmc Is exposure to formaldehyde in air causally associated with leukemia?--A hypothesis-based weight-of-evidence analysis
    Lorenz R Rhomberg
    Gradient, Cambridge, Massachusetts 02138, USA
    Crit Rev Toxicol 41:555-621. 2011
    ..Animal studies generally report neither hematotoxicity nor leukemia associated with formaldehyde inhalation, and hematotoxicity studies in humans are inconsistent...
  49. doi Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
    J A McCubrey
    Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA
    Leukemia 22:708-22. 2008
    The Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways are frequently activated in leukemia and other hematopoietic disorders by upstream mutations in cytokine receptors, aberrant chromosomal translocations as well as other genetic ..
  50. doi The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose
    Xazmin H Lowman
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
    Mol Cell 40:823-33. 2010
    ..We propose that Noxa plays both growth-promoting and proapoptotic roles in hematopoietic cancers with phospho-S(13) as the glucose-sensitive toggle switch controlling these opposing functions...
  51. ncbi Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1060-6. 2008
    ..SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia. A phase 1 study was conducted to evaluate the safety and activity of oral vorinostat 100 to 300 mg twice or ..
  52. pmc Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles
    Jun Wang
    Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China
    Int J Nanomedicine 6:203-11. 2011
    ..A promising approach to optimize the disposition of daunorubicin-loaded magnetic nanoparticles (DNR-MNPs) was developed to minimize serious side effects of systematic chemotherapy for cancer...
  53. pmc CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia
    Sara Gonzalez-Garcia
    Centro de Biologia Molecular Severo Ochoa, Consejo Superior de Investigaciones Cientificas, Universidad Autonoma de Madrid, Spain
    J Exp Med 206:779-91. 2009
    ..Thus, Notch1 controls early T cell development, in part by regulating the stage- and lineage-specific expression of IL-7Ralpha...
  54. pmc MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia
    Hua Zhang
    Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory for Biocontrol, Sun Yat Sen University, Guangzhou, PR China
    PLoS ONE 4:e7826. 2009
    ..indicated that microRNAs (miRNAs) play a critical role in malignancies, and regulations in the progress of adult leukemia. The role of miRNAs in pediatric leukemia still needs to be established...
  55. doi The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice
    Yanmei Li
    Department of Medical Biophysics, University of Toronto, and Program in Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, ON, Canada
    Blood 119:4486-98. 2012
    ..This miR-17-92 expression signature was also detected in p53- B-cell chronic lymphocytic leukemia patients displaying an aggressive clinical phenotype...
  56. ncbi Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells
    Changjiang Weng
    Center for Molecular Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China 100080
    J Biol Chem 280:10491-500. 2005
    ..These results suggested that removal of N-terminal domains of Bid by caspase-8 and Mcl-1 by caspase-3 enabled the maximal mitochondrial perturbation that potentiated TRAIL-induced apoptosis...
  57. ncbi Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells
    Hiroshige Hibasami
    Faculty of Medicine, Mie University, Tsu City, Mie 514 0001, Japan
    Int J Mol Med 17:215-9. 2006
    ..glycyrrhetic acid (GR) which is metabolic substance of glycyrrhizin, on DNA of human hepatoma (HLE), promyelotic leukemia (HL-60) and stomach cancer (KATO III) cells. GR displayed apoptotic effects against HLE, HL-60 and KATO III cells...
  58. ncbi Zerumbone, a bioactive sesquiterpene, induces G2/M cell cycle arrest and apoptosis in leukemia cells via a Fas- and mitochondria-mediated pathway
    Mingji Xian
    Department of Internal Medicine, Division of Hematology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku Tokyo, 160 8582 Japan
    Cancer Sci 98:118-26. 2007
    ..that zerumbone (ZER), a natural cyclic sesquiterpene, significantly suppressed the proliferation of promyelocytic leukemia NB4 cells among several leukemia cell lines, but not human umbilical vein endothelial cells (HUVECs), by inducing ..
  59. pmc Leukaemogenesis: more than mutant genes
    Jianjun Chen
    Department of Medicine, University of Chicago, IL 60637, USA
    Nat Rev Cancer 10:23-36. 2010
    ..The genetic heterogeneity of acute leukaemias poses therapeutic challenges, but pharmacological agents that target components of the epigenetic machinery are promising as a component of the therapeutic arsenal for this group of diseases...
  60. doi MicroRNA and leukemia: tiny molecule, great function
    Haifeng Zhao
    State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin 300020, PR China
    Crit Rev Oncol Hematol 74:149-55. 2010
    ..It is known that aberrant microRNA expression can play a vital role in the pathology of leukemia, thus microRNAs have rapidly emerged as potential targets for therapeutics...
  61. ncbi Hox genes in hematopoiesis and leukemogenesis
    B Argiropoulos
    Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
    Oncogene 26:6766-76. 2007
    ..Given the documented role of Hox genes in hematopoiesis and leukemogenesis, we propose that Hox-dependent pathways are closely linked to the self-renewal program crucial to the origin and function of leukemic stem cells...
  62. ncbi AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo
    Jing Yang
    Department of Hematology and Respiratory Medicine, Kochi University, Nankoku, Kochi, Japan
    Blood 110:2034-40. 2007
    ..We have recently shown that hematopoietic malignant cells including those from acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) aberrantly expressed Aurora A and B kinases, and ZM447439, a potent ..
  63. doi Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
    L S Steelman
    Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA
    Leukemia 22:686-707. 2008
    ..Aberrant regulation of the survival pathways can contribute to uncontrolled cell growth and lead to leukemia. In this review, we describe the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT signaling cascades and summarize ..
  64. ncbi Therapy-related leukemia and myelodysplasia: susceptibility and incidence
    Giuseppe Leone
    Istituto di Ematologia, Universita Cattolica S Cuore, L go A Gemelli, 1, 00168 Rome, Italy
    Haematologica 92:1389-98. 2007
    Therapy-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) is an increasingly recognized treatment complication in patients treated with radiotherapy or chemotherapy for previous hematologic malignancies or solid tumors...
  65. pmc AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia
    Chengqi Lin
    Stowers Institute for Medical Research, 1000 East 50th Street, Kansas City, MO 64110, USA
    Mol Cell 37:429-37. 2010
    Chromosomal translocations involving the MLL gene are associated with infant acute lymphoblastic and mixed lineage leukemia. There are a large number of translocation partners of MLL that share very little sequence or seemingly functional ..
  66. ncbi The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells
    Baisong Liao
    Department of Molecular Genetics, Microbiology, and Immunology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854, USA
    J Biol Chem 280:18517-24. 2005
    ..Using human K562 leukemia cells as a model, we show that IMP-3 protein associates with IGF-II leader-3 and leader-4 mRNAs and H19 RNA but ..
  67. pmc The leukemia-associated Mllt10/Af10-Dot1l are Tcf4/β-catenin coactivators essential for intestinal homeostasis
    Tokameh Mahmoudi
    Hubrecht Institute and University Medical Centre Utrecht, Utrecht, The Netherlands
    PLoS Biol 8:e1000539. 2010
    ..Using proteomics, we identified the leukemia-associated Mllt10/Af10 and the methyltransferase Dot1l as Tcf4/β-catenin interactors in mouse small intestinal ..
  68. ncbi Selective laser nano-thermolysis of human leukemia cells with microbubbles generated around clusters of gold nanoparticles
    Dmitri O Lapotko
    Luikov Heat and Mass Transfer Institute, Minsk, 220072, Belarus
    Lasers Surg Med 38:631-42. 2006
    ..The objective of this study was two-fold: to optimize NP targeting to real tumor (human) cells and to better understand physical mechanisms of cell damage for improved control of the laser ablation...
  69. ncbi Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program
    J Gabert
    Department of Hematology Biology, Institut Paoli Calmettes, France
    Leukemia 17:2318-57. 2003
    ..information for treatment stratification in several types of leukemias such as childhood acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and acute promyelocytic leukemia...
  70. ncbi E2A basic helix-loop-helix transcription factors in human leukemia
    David P LeBrun
    Department of Pathology, Queen s University, Kingston, Ontario, Canada
    Front Biosci 8:s206-22. 2003
    ..chromosome 19 is involved in recurrent chromosomal rearrangements associated with pediatric acute lymphoblastic leukemia. The resulting fusion of 5' E2A sequences with 3' portions of other genes leads to the expression of two well-..
  71. doi MicroRNAs in acute leukemia: from biological players to clinical contributors
    D Schotte
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Leukemia 26:1-12. 2012
    ..As a consequence, miRNA dysregulation causes disruption of the hematopoietic system and leukemia may arise...
  72. doi The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells
    Sumaiya Sharmeen
    Princess Margaret Hospital, Ontario Cancer Institute, Toronto, ON, Canada
    Blood 116:3593-603. 2010
    ..anticancer activity, we compiled and screened a library of such compounds to identify agents cytotoxic to leukemia cells...
  73. pmc viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia
    El Ad David Amir
    Department of Biological Sciences, Columbia Initiative for Systems Biology, Columbia University, New York, New York, USA
    Nat Biotechnol 31:545-52. 2013
    ..Healthy bone marrow automatically maps into a consistent shape, whereas leukemia samples map into malformed shapes that are distinct from healthy bone marrow and from each other...
  74. pmc Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells
    Hiroko Tadokoro
    From the Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Science, Tokyo 192 0392, Japan
    J Biol Chem 288:34343-51. 2013
    ..This study aimed to clarify whether hypoxia affects angiogenic function through exosomes secreted from leukemia cells...
  75. pmc An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance
    Johannes Zuber
    Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA
    Genes Dev 25:1628-40. 2011
    ..programs that underlie addiction to MLL-AF9-a fusion oncoprotein involved in aggressive forms of acute myeloid leukemia (AML)...
  76. doi Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene expression in human leukemia U937 cells
    Dong Oh Moon
    Faculty of Applied Marine Science, Cheju National University, Jeju Special Self Governing Province, 690 756, South Korea
    Cancer Lett 264:192-200. 2008
    ..and the molecular mechanisms of gossypol on NF-kappaB activation and NF-kappaB-related gene expression in human leukemia U937 cells...
  77. doi The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia
    Roel Polak
    Department of Hematology, Erasmus Medical Center, Dr Molewaterplein 50, Rotterdam, The Netherlands
    Blood 119:911-23. 2012
    ....
  78. doi Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
    E J Feldman
    Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, USA
    Leuk Res 36:1283-9. 2012
    ..The unique pharmacologic features of CPX-351 contribute to its promising antileukemic efficacy...
  79. pmc A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia
    Steven W Paugh
    Departments ofBiochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA 23298 0614, USA
    Blood 112:1382-91. 2008
    ..Expression of SphK1 is up-regulated in cancers, including leukemia, and associated with cancer progression...
  80. doi Naringenin induces apoptosis through downregulation of Akt and caspase-3 activation in human leukemia THP-1 cells
    Joon Hee Park
    Department of Molecular Biology, Dongeui University, South Korea
    Food Chem Toxicol 46:3684-90. 2008
    ..Herein, we investigated NEGN's pro-apoptotic effect on human leukemia THP-1 cells...
  81. pmc T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
    Michael Kalos
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Sci Transl Med 3:95ra73. 2011
    ..clinical activity after infusion in three of three patients treated with advanced chronic lymphocytic leukemia (CLL)...
  82. doi Janus kinase deregulation in leukemia and lymphoma
    Edwin Chen
    Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
    Immunity 36:529-41. 2012
    ....
  83. doi Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia
    Tullia Maraldi
    Department of Anatomy and Histology and CIPro Proteomics Centre, University of Modena and Reggio Emilia, I 41100 Modena, Italy
    Int J Oncol 38:427-35. 2011
    ..In the current study, lysates from parental and multidrug resistant (MDR) CEM leukemia cells were spotted onto reverse-phase protein microarrays and probed with a panel of phospho-antibodies to ERK, ..
  84. pmc Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase
    Susmita Mondal
    Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, A Unit of Council of Scientific and Industrial Research, Govt, of India 4, Raja S, C, Mullick Road, Kolkata 700032, India
    Mol Cancer 9:239. 2010
    ..It is a specific and potent inducer of apoptosis and suppressor of cell growth. In leukemia, chemoresistance generally developed due to deregulated ceramide metabolism...
  85. pmc Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging
    Emanuela Messa
    Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Regione Gonzole 10, 10043 Orbassano, Torino, Italy
    Haematologica 95:1308-16. 2010
    ..Nuclear factor-kappaB is a key regulator of many cellular processes and its impaired activity has been described in different myeloid malignancies including myelodysplastic syndromes...
  86. pmc Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines
    Constance J Glover
    Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    Biochem Pharmacol 73:331-40. 2007
    ..profiles of the five inhibitors toward the NCI's tumor cell lines revealed that they were cytotoxic to the leukemia subpanel (particularly K562 cells)...
  87. pmc Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment
    Cliona M McHale
    Division of Environmental Health Sciences, Genes and Environment Laboratory, School of Public Health, University of California, Berkeley, CA 94720 7356, USA
    Carcinogenesis 33:240-52. 2012
    Benzene causes acute myeloid leukemia and probably other hematological malignancies...
  88. pmc Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis
    Abdul Khalade
    Institute of Occupational and Environmental Medicine, University of Birmingham, UK
    Environ Health 9:31. 2010
    ..epidemiologic studies have provided estimates of the relation between exposure to benzene at work and the risk of leukemia, but the results have been heterogeneous...
  89. doi Array-based genomic resequencing of human leukemia
    Y Yamashita
    Division of Functional Genomics, Jichi Medical University, Tochigi, Japan
    Oncogene 29:3723-31. 2010
    To identify oncogenes in leukemias, we performed large-scale resequencing of the leukemia genome using DNA sequence arrays that determine approximately 9 Mbp of sequence corresponding to the exons or exon-intron boundaries of 5648 protein-..
  90. doi Selective growth inhibition of human leukemia and human lymphoblastoid cells by resveratrol via cell cycle arrest and apoptosis induction
    Sau K Lee
    Department of Medical Biotechnology, School of Medicine, Flinders University, GPO Box 2100, Adelaide, SA 5001, Australia
    J Agric Food Chem 56:7572-7. 2008
    ....
  91. doi Target of rapamycin signaling in leukemia and lymphoma
    Collin Vu
    Division of Hematology Oncology, Department of Medicine, University of California Irvine, CA 92697, USA
    Clin Cancer Res 16:5374-80. 2010
    ..Here we discuss different strategies to inhibit TOR for the treatment of leukemia, lymphoma, and myeloma. The TOR enzyme exists in two complexes in cells, TORC1 and TORC2...
  92. doi Epigenomics of leukemia: from mechanisms to therapeutic applications
    Cristina Florean
    Laboratoire de Biologie Moléculaire et Cellulaire de Cancer, Hopital Kirchberg, 9, rue Edward Steichen, L 2540 Luxembourg, Luxembourg
    Epigenomics 3:581-609. 2011
    ..Clinically and pathologically, leukemia is subdivided into four main categories: chronic lymphocytic leukemia, chronic myeloid leukemia, acute ..
  93. ncbi Tanshinone IIA inhibits leukemia THP-1 cell growth by induction of apoptosis
    Jia Jun Liu
    Department of Hematology, The Third Affiliated Hospital of Sun Yat Sen University, Guangzhou 510630, PR China
    Oncol Rep 21:1075-81. 2009
    ..was undertaken to investigate the in vitro antiproliferation and apoptosis inducing effects of Tanshinone IIA on leukemia THP-1 cell lines and its mechanisms of action...
  94. pmc Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality
    Lara S Collier
    Department of Genetics, Masonic Cancer Center and Masonic Cancer Center Histopathology Core, University of Minnesota, Minneapolis, Minnesota, USA
    Cancer Res 69:8429-37. 2009
    ..In previous studies, efficient leukemia/lymphoma formation on an otherwise wild-type genetic background occurred in mice undergoing whole-body ..
  95. pmc Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin
    Jun Wang
    Department of Hematology, Zhongda Hospital, Medicine College, People s Republic of China
    Int J Nanomedicine 6:1027-34. 2011
    ..acting as a drug depot system for the sustained release of the loaded DNR and BrTet, in the drug resistant human leukemia K562/A02 cells and further to explore potential mechanisms...
  96. doi Graft-versus-leukemia effects of transplantation and donor lymphocytes
    Hans Jochem Kolb
    Department of Medicine 3, Hematopoietic Cell Transplantation, University of Munich and Helmholtz Zentrum Muenchen National Research Centre for Environmental Health, Munich, Germany
    Blood 112:4371-83. 2008
    Allogeneic transplantation of hematopoietic cells is an effective treatment of leukemia, even in advanced stages...
  97. doi Selective induction of apoptosis through activation of caspase-8 in human leukemia cells (Jurkat) by dandelion root extract
    P Ovadje
    Department of Chemistry and Biochemistry, University of Windsor, Windsor, ON, Canada
    J Ethnopharmacol 133:86-91. 2011
    ..have been used in traditional Native American Medicine and Traditional Chinese Medicine (TCM) for treatment of leukemia and breast cancer; however, the mechanism of action remains unknown...
  98. ncbi Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program
    E Beillard
    Department of Hematological Biology, Institute Paoli Calmettes, Marseille, France
    Leukemia 17:2474-86. 2003
    ..A multicenter retrospective study on over 250 acute and chronic leukemia samples obtained at diagnosis and with an identified FG transcript confirmed that the three CGs had a stable ..
  99. doi Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
    Elena Provasi
    Experimental Hematology Unit, Division of Regenerative Medicine, Gene Therapy and Stem Cells, Program of Immunology, Gene Therapy and Bio Immunotherapy of Cancer, Leukemia Unit, San Raffaele Scientific Institute, Milan, Italy
    Nat Med 18:807-15. 2012
    ....
  100. doi Mixed lineage leukemia: roles in gene expression, hormone signaling and mRNA processing
    Khairul I Ansari
    Department of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX 76019, USA
    FEBS J 277:1790-804. 2010
    ..In this minireview, we summarize recent advances in understanding the roles of MLLs in gene regulation and hormone signaling and highlight their potential roles in mRNA processing...
  101. ncbi Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia
    Takuya Matsunaga
    Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine, South 1, West 16, Chuo Ku, Sapporo 060 0061, Japan
    Nat Med 9:1158-65. 2003
    Bone-marrow minimal residual disease (MRD) causes relapse after chemotherapy in patients with acute myelogenous leukemia (AML)...

Research Grants79

  1. NIEHS SUPPORT OF THE AHS COHORT STUDY AT NCI
    Charles Knott; Fiscal Year: 2010
    ..Analysis of NHL and leukemia is now underway...
  2. THE AGRICULTURAL HEALTH STUDY - FIELD STATIONS
    Charles Lynch; Fiscal Year: 2010
    ..Analysis of NHL and leukemia is now underway...
  3. Mapping for Specialized Domains for FCeRI Signaling &Internalization
    Bridget S Wilson; Fiscal Year: 2013
    ..Results in the rat basophilic leukemia (RBL-2H3) cell line will be confirmed in BMMCs...
  4. Bone Deficits and Excess Adiposity after Pediatric Bone Marrow Transplantation
    Sogol Mostoufi-Moab; Fiscal Year: 2013
    ..of bone density and structure in children and adolescents after completion of therapy for acute lymphoblastic leukemia (manuscript under review), and a second study examining skeletal complications of growth hormone therapy in ..
  5. Cardiotrophin-Like Cytokine 1, a Candidate Molecule for the FSGS Factor
    Virginia J Savin; Fiscal Year: 2010
    ..the expression of each of the components of the receptors for CLC- 1 (gp 130, CNTF receptor-1 (CNTFR-1), and leukemia inhibitory factor receptor (LIFR)) by glomeruli and cultured using RT-PCR and Western blotting...
  6. GENETIC ANALYSIS OF POLARITY
    RUTH M STEWARD; Fiscal Year: 2010
    ..In the bone marrow and blood of leukemia patients, we have detected high levels of a smaller form of PDCD2, PDCD233, barely detected in samples from ..
  7. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
    Paul J Shami; Fiscal Year: 2012
    ..In mouse xenograft models of human tumors, JS-K is highly effective against acute myeloid leukemia, prostate cancer, hepatocellular carcinoma, multiple myeloma and non-small cell lung cancer...
  8. Inhibition of IkK to treat lethal Graft-vs.-Host Disease
    Patrick Flood; Fiscal Year: 2009
    Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma...
  9. Community Participation Research of Breastfeeding Disparities in African American
    Tamar Ringel Kulka; Fiscal Year: 2009
    ..eczema, asthmatic episodes, type I and type II diabetes, episodes of infant diarrhea, and incidents of childhood leukemia and sudden death syndrome...
  10. Transgenesis and Xenotransplantation
    Jorge A Piedrahita; Fiscal Year: 2013
    ..normal and abnormal immune system development and function, study development and treatment for diseases such as leukemia, looking at disease progression and the development of vaccines for diseases such as AIDS, and study human tumor ..
  11. ICSBP Function During Myeloid Differentiation
    ELIZABETH ANN EKLUND; Fiscal Year: 2011
    ..of evidence suggest that the interferon consensus sequence binding protein (ICSBP or IRF8) functions as a myeloid leukemia tumor-suppressor...
  12. Twenty-second Annual Fanconi Anemia Research Fund Scientific Symposium
    GROVER CARLTON BAGBY; Fiscal Year: 2010
    ..by bone marrow failure, developmental anomalies, a high incidence of myelodysplasia (MDS), acute non-lymphocytic leukemia (AML), solid tumors, and cellular hypersensitivity to cross-linking agents...
  13. 24th Annual Fanconi Anemia Research Fund Scientific Symposium
    GROVER CARLTON BAGBY; Fiscal Year: 2012
    ..by bone marrow failure, developmental anomalies, high incidence of myelodysplasia (MDS), acute non-lymphocytic leukemia (AML), solid tumors, and cellular hypersensitivity to cross-linking agents...
  14. TARGETING THE MARCKS-FAMILY PROTEINS TO INHIBIT NEUTROPHIL MIGRATION
    Mary K Sheats; Fiscal Year: 2013
    ..will be performed using primary human neutrophils isolated from healthy volunteers as well as a promyelocitic leukemia cell line (HL60s) that can be induced to look and behave like primary neutrophils...
  15. Cell signaling as a leukemia biomarker
    JAMES WILLIAM JACOBBERGER; Fiscal Year: 2013
    ..b>Leukemia is an evolutionary process that works by clonal selection...
  16. Arsenic Trioxide and Acute Myeloid Leukemia
    Yongkui Jing; Fiscal Year: 2012
    ..DESCRIPTION (provided by applicant): The outstanding therapeutic success of As2O3 in a subtype of acute myelocytic leukemia (AML), the acute promyelocytic leukemia (APL), prompted widespread effort to extend this therapy to other ..
  17. Chemical modulators of Tet-family proteins
    Anjana Rao; Fiscal Year: 2010
    ..ii) TET1 is an MLL partner in acute myeloid and lymphoid leukemia (AML, ALL), and TET2 is implicated in myelodysplastic syndromes and AML...
  18. Exome re-sequencing candidate loci for familial essential tremor
    Barry E Kosofsky; Fiscal Year: 2012
    ..By using this technology, we recently identified missense mutations in a novel gene, feline leukemia virus subgroup C receptor 1 gene, as the cause of the Mendelian disorder, posterior column ataxia and retinitis ..
  19. Molecular Mechanisms of Disease Progression in Myeloid Malignancy
    ELIZABETH ANN EKLUND; Fiscal Year: 2013
    ..Fas-resistance, and increased bcatenin activity are associated with poor prognosis in chronic myeloid leukemia (CML)...
  20. Integrated signaling of eicosanoids in HSC formation and regeneration
    Trista E North; Fiscal Year: 2013
    ..Defects in HSC formation or differentiation can lead to devastating diseases in childhood or to leukemia. The first HSCs arise in the embryo from an area encompassing the dorsal aorta, termed the aorta-gonad ..
  21. Cellular and Animal Models of FUS Mutations in ALS
    Eric J Huang; Fiscal Year: 2013
    ..chromosome 16 is originally identified to encode an oncogene implicated in malignant liposarcoma and myeloid leukemia. More recent evidence shows that mutations in FUS/TLS are found in familial cases of amyotrophic lateral ..
  22. Cell Cycle Regulation and Adult T Cell Leukemia
    Chou Zen Giam; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): HTLV-I is the causative agent of adult T-cell leukemia/lymphoma (ATL), a malignancy of CD4+ T cells whose etiology is associated with the viral transactivator/oncoprotein, Tax...
  23. Signaling by Cytoplasmic Tyrosine Kinases in Leukocytes
    Clifford A Lowell; Fiscal Year: 2013
    ..This will lead to better design of therapeutcs to target immune diseases, as well as leukemia and lymphoma.
  24. Molecular Mechanism of Immune Therapy for Bone Marrow Failures
    Pearlie K Epling-Burnette; Fiscal Year: 2013
    ..The broad long-term goal of this proposal is to improve the diagnosis and treatment of patients with LGL leukemia and these other bone marrow failure diseases...
  25. PRE- AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGY
    J Evan Sadler; Fiscal Year: 2013
    ..in mammalian cells;role of platelets and angiogenesis in metastasis;biology of human immunodeficiency and leukemia viruses;epithelial morphogenesis;pathogenesis of leukemia, MDS, myeloproliferative neoplasms, and congenital ..
  26. 14th International Workshop on Ataxia-Telangiectasia and ATM
    Richard A Gatti; Fiscal Year: 2010
    ..genomic instability, radiation sensitivity, and a markedly increased incidence of cancer, usually lymphoma or leukemia. It has been estimated that 1-6% of the general population carries mutations in one allele of the ATM (ataxia-..
  27. Molecular Pathogenesis of MDS and CMML
    Jaroslaw P Maciejewski; Fiscal Year: 2013
    ..of patients with MDS and found that UPD11q was particularly frequent in patients with chronic myelomonocytic leukemia. By sequencing the c-Cbl gene, an E3 ubiquitin ligase in this chromosomal region, a mutation involving a critical ..
  28. SATB1-dependent epigenetic regulation of leukemia initiating cells
    Britta Will; Fiscal Year: 2011
    ..of specific factors in these transcriptional networks disrupts normal HSC function and leads to the formation of leukemia initiating cells (LIC), superordinate gene expression regulation by epigenetic mechanisms, is still poorly ..
  29. Cellular and Molecular Regulation of Thrombopoiesis
    Ramesh A Shivdasani; Fiscal Year: 2012
    ..Acute clotting in the heart, brain and other sites is a major cause of suffering and death;conversely, cancer and leukemia treatments frequently reduce platelet numbers, causing therapy to be aborted or suspended...
  30. Validation of microRNAs as therapeutic targets in hematological malignancies
    Natarajan Muthusamy; Fiscal Year: 2013
    ..Both chronic and acute leukemia's have been regarded as suitable for this therapeutic approach because of the occurrence of non-random ..
  31. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2013
    Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) currently kill the majority of afflicted patients despite treatment with combination chemotherapy and hematopoietic cell transplantation (HCT)...
  32. The Role of CD5 in B-Cell Development and Autoimmunity
    Chander Raman; Fiscal Year: 2012
    ..The most prevalent B-cell malignancy, chronic lymphocytic leukemia (CLL) is CD5+ B-cell in origin...
  33. Novel Hematopoietic Conditioning Agents for Treatment of Hematological Diseases
    Olga B Chernova; Fiscal Year: 2010
    ..a small molecule (SM27) that selectively kills cells of hematopoietic origin, including a panel of human leukemia cell lines, normal human blood cells and mouse bone marrow cells...
  34. T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia
    Laurence J N Cooper; Fiscal Year: 2013
    ..provided by applicant): This revised R01 grant addresses the problem of relapse of B-lineage acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem-cell transplantation (HSCT)...
  35. Development of a Porcine Model of Ataxia-Telangiectasia
    Christopher Rogers; Fiscal Year: 2011
    ..also exhibit a number of other clinical symptoms including increased susceptibility to cancer (lymphomas, leukemia, brain tumors), immunodeficiency, insulin-resistant diabetes, chromosomal instability, sensitivity to ionizing ..
  36. Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia
    Andrew Napper; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Childhood leukemia that develops following rearrangement of the mixed lineage leukemia (MLL) gene to give MLL fusion proteins is aggressive and very difficult to treat...
  37. Analysis of the leukemic stem cell niche in chronic myeloid leukemia
    DANIELA SANDRA KRAUSE; Fiscal Year: 2013
    ..in hematology/oncology and clinical pathology/ transfusion medicine and basic research training on the study of leukemia. I am applying for a Mentored Clinical Scientist Development Award (K08) in order to have protected time to ..
  38. Twenty-first Annual Fanconi Anemia Research Fund Scientific Symposium
    Grover Bagby; Fiscal Year: 2009
    ..by bone marrow failure, developmental anomalies, a high incidence of myelodysplasia (MDS), acute non-lymphocytic leukemia (AML), solid tumors, and cellular hypersensitivity to cross-linking agents...
  39. Using Mass Spectroscopy to Characterize Transcription Proteins and F2-Isoprostane
    BETTYE HENNINTON; Fiscal Year: 2011
    ..for a human homolog, MLL3, that is found on a region of chromosome 7 that is frequently deleted in myeloid leukemia (3)...
  40. The Role of PKR in a Novel IL-3 Signal Transduction Pathway
    William Stratford May; Fiscal Year: 2012
    ..cellular stress in hematopoietic cells and 2) determine the significance of PKR in MDS progression to acute leukemia. For these studies we will use molecular biochemical and cell culture approaches and make use of the NUP98- ..
  41. Post-translational regulation of MLL in leukemogenesis
    ANDREW GEORGE MUNTEAN; Fiscal Year: 2012
    ..transcription factor that regulates the expression of HOX genes, which are required for MLL induced leukemia. Translocations of the MLL gene fuse the N-terminus of MLL to one of more than 60 different translocation ..
  42. Post-translational regulation of MLL in leukemogenesis
    ANDREW GEORGE MUNTEAN; Fiscal Year: 2013
    ..transcription factor that regulates the expression of HOX genes, which are required for MLL induced leukemia. Translocations of the MLL gene fuse the N-terminus of MLL to one of more than 60 different translocation ..
  43. Characterization of Genetic Abnormalities in MDS and Their Clinical Impact
    Rafael Bejar; Fiscal Year: 2013
    ..of hematopoiesis that cause inefficient blood cell production, low blood counts, and risk of progression to acute leukemia. The prognosis for patients with MDS is highly variable, with some only mildly affected while others succumb ..
  44. Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders
    Bruce S Bochner; Fiscal Year: 2013
    ..with varying prognoses depending on the extent of involvement, but Aggressive Systemic Mastocytosis and Mast Cell Leukemia are always fatal due to the lack of effective treatments...
  45. Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders
    Bruce S Bochner; Fiscal Year: 2012
    ..with varying prognoses depending on the extent of involvement, but Aggressive Systemic Mastocytosis and Mast Cell Leukemia are always fatal due to the lack of effective treatments...
  46. IL-22 in epithelial regeneration after allogeneic transplant
    Alan Hanash; Fiscal Year: 2013
    ..b>leukemia/lymphoma (GVL) responses...
  47. Chromatin regulation by human SIRT7 in aging-associated cellular programs
    Katrin F Chua; Fiscal Year: 2013
    ..SIRT7 is on a chromosomal region that is frequently mutated acute leukemia, lymphoma, and other aging-associated cancers, and SIRT7 protein levels are increased in tumor tissues...
  48. Chemical approaches for studying the biology of CD38
    Hening Lin; Fiscal Year: 2013
    ..other types of cells, and its deregulation is found to contribute to several different human diseases, including leukemia, social behavior defects, diabetes, and osteoporosis...
  49. Human Platelet Defects in Transcription Factor RUNX1 Haplodeficiency
    ANGARA KONETI RAO; Fiscal Year: 2013
    ..is associated with familial thrombocytopenia, impaired platelet function and predisposition to acute leukemia. Our patient has mild thrombocytopenia, markedly abnormal aggregation and secretion associated with diminished ..
  50. ROCK inhibitor suppression of GVHD with retention of GVL response
    Sujatha Iyengar; Fiscal Year: 2012
    ..following ablation of the patient's hematapoietic system is a life-saving treatment for several types of leukemia. Acute graft vs...
  51. Mechanisms of cancer initiation by TRIM32
    Molly F Kulesz-Martin; Fiscal Year: 2012
    ..is prognostic for conversion from myelodysplastic syndrome (MDS) to later stages and chronic myeloid leukemia (CML)...
  52. SIGNALING THROUGH RHO GTP/GDP EXCHANGE FACTORS
    Philip B Wedegaertner; Fiscal Year: 2013
    ..The research proposed in this application will focus on one RGS-RhoGEF, termed leukemia-associated RhoGEF (LARG)...
  53. Development of a Porcine Model of Ataxia-Telangiectasia
    Christopher Rogers; Fiscal Year: 2013
    ..also exhibit a number of other clinical symptoms including increased susceptibility to cancer (lymphomas, leukemia, brain tumors), immunodeficiency, insulin-resistant diabetes, chromosomal instability, sensitivity to ionizing ..
  54. Functional analysis of mDia formins in hematopoietic stem cell engraftment and mi
    Peng Ji; Fiscal Year: 2010
    ..many blood related diseases such as aplastic anemia, fanconi anemia, sickle cell anemia, beta thalassemia major, leukemia, lymphomas, multiple myeloma, and many immune deficiency disorders...
  55. Genome instability in leukemia stem cell
    Tomasz Skorski; Fiscal Year: 2010
    ..leukemogenic only when expressed in a hematopoietic stem cells (HSCs) with self-renewal capacity thereby inducing leukemia stem cell (LSC)...
  56. FASEB SRC on Hematopoietic Malignancies
    MICHELLE ALICE KELLIHER; Fiscal Year: 2011
    ..highlight recent advances in biology and treatment of a wide spectrum of blood cancers, including acute myeloid leukemia, acute lymphoid leukemia, myeloma, myeloproliferative neoplasms and myeloproliferative diseases...
  57. Developing a prediction model for vincristine-induced peripheral neuropathy
    Jamie L Renbarger; Fiscal Year: 2010
    ..that vincristine pharmacokinetics may be associated with long-term outcomes in children with acute lymphoblastic leukemia (ALL)...
  58. Functional Genomics Approach to the Role of the JAK/STAT and MAPK Pathway in CBD
    Li Li; Fiscal Year: 2013
    ..Her research focused on the development of novel immunotherapeutic strategies for patients with acute myeloid leukemia (AML)...
  59. HTLV-1 &Cellular Factors in Neuroinflammatory Disease
    Brian Wigdahl; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukemia (ATL) and the neurological disorder, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)...
  60. Role of FA proteins in hematopoiesis
    Qishen Pang; Fiscal Year: 2013
    ..stem and progenitor (HSC/P) cells, and progression to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)...
  61. Define the role of dendritic cells in HTLV-1 associated neuroinflammatory disease
    Pooja Jain; Fiscal Year: 2013
    ..Consequently, human T cell leukemia virus type 1 (HTLV-1) has been used as a model pathogen to explore the role of DCs in virus- induced ..
  62. ROS, Redox Regulation and Novel Targets for Cancer Therapy
    Peng Huang; Fiscal Year: 2013
    ..Our recent study showed that chronic lymphocytic leukemia (CLL) cells exhibited intrinsic oxidative stress and were highly dependent on cellular antioxidants such as ..
  63. Targeting the leukemia microenvironment by CXCR4 inhibition in stem cell transpla
    Marina Y Konopleva; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The prognosis of patients with relapsed acute myeloid leukemia (AML) is extremely poor...
  64. MAPPING AND CLONING TRANSLOCATION BREAKPOINTS
    Janet Rowley; Fiscal Year: 2004
    DESCRIPTION: (adapted from the applicant's abstract) Malignant cells from human leukemia and lymphoma have a very high frequency of chromosome abnormalities, especially translocations...
  65. Novel Screen for Targeted CLL Therapeutics
    Dale Christensen; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Of the nearly 84,000 cases of leukemia in the Western world, B-cell chronic lymphocytic leukemia (B-CLL) is the most common and accounts for approximately 30% of all adult leukemia cases...
  66. INTERACTION OF AMINOTHIOLS AND ALKYLATING AGENTS
    Frederick Valeriote; Fiscal Year: 1990
    ..to define the cellular and molecular basis for the potentiation of the cytotoxicity of nitrogen mustard (HN2) to leukemia cells observed following aminothiol pretreatment...
  67. Pre-BCR Function Selecting Novel B Cell Receptors in Chronic Lymphocytic Leukemia
    Kyoko Hayakawa; Fiscal Year: 2010
    ..B cell chronic lymphocytic leukemia (CLL) is the most common leukemia affecting adults in Western countries and is recognized by the accumulation of ..
  68. Biomarkers of Formaldehyde Exposure and Toxicity
    Luoping Zhang; Fiscal Year: 2010
    ..cancer and also concluded that there is "strong but not sufficient evidence for a causal association between leukemia and occupational exposure to formaldehyde"...
  69. Childhood Leukemia and Home Environmental Exposures
    Patricia A Buffler; Fiscal Year: 2010
    DESCRIPTION: Previous attempts to link leukemia risks to children's home exposures relied upon indirect measuresof exposures to carcinogens, based on interviews of households and outdoor levels predicted by Geographic Information ..
  70. Lenalidomide Treatment and the Chronic Lymphocytic Leukemia Microenvironment
    Thomas J Kipps; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western world and is considered incurable...
  71. DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA
    Jerry Radich; Fiscal Year: 1993
    The assessment of remission in the treatment of leukemia provides the strongest measure of therapeutic outcome and prognostication...
  72. Single Cell Diagnosis of Leukemia using Multiplex Nested PCR System
    WINSTON Z HO; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Single Cell Diagnosis of Leukemia using Multiplex Nested PCR System...
  73. Role of histone methyltransferases hDOTIL in leukemogenesis
    Yi Zhang; Fiscal Year: 2009
    ..Two proteins that we identified are AF10 and ENL, both of which are MLL (mix lineage leukemia) fusion partner involved in acute myeloid leukemia...
  74. EPIDEMIOLOGY OF INFANT LEUKEMIA
    Julie Ross; Fiscal Year: 2007
    ..Infants with leukemia may represent another such rare group...
  75. Experimental Therapeutics in Acute Leukemias
    William G Blum; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The majority of adults with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) eventually relapse, and those with relapsed disease have a high likelihood of treatment failure with ..
  76. BIOMARKERS OF TREATMENT RELATED LEUKEMIA
    CAROLYN FELIX; Fiscal Year: 2004
    ..of this work is to develop new avenues to identify undergoing anticancer therapy who are at increased risk of leukemia as a treatment complication and to facilitate detection of the leukemic clone earlier in the course of the ..
  77. PROTEINASE 3 SPECIFIC IMMUNOTHERAPY OF LEUKEMIA
    Jeffrey Molldrem; Fiscal Year: 2002
    A significant graft versus leukemia (GVL) immune response, mediated by donor lymphocytes after allogeneic bone marrow transplantation (BMT), contributes to the cure of 40-50 percent of adult patients with myeloid leukemias...
  78. GENOMIC ANALYSIS OF ADOLESCENT AND YOUNG ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
    Cheryl L Willman; Fiscal Year: 2010
    ..Project title: Genomic Analysis of Adolescent and Young Adult Acute Lymphoblastic Leukemia Acute lymphoblastic leukemia (ALL) is one of the leading causes of cancer related death in the adolescent and ..
  79. Identifying the spectrum of genetic alterations in high risk ALL
    CHARLES G contact MULLIGHAN; Fiscal Year: 2010
    ..to identify genetic alterations contributing to the pathogenesis and treatment outcome of high risk acute leukemia. Despite best current therapy, acute lymphoblastic leukemia remains a leading cause of cancer- related death in ..